Milk Polar Lipids Favorably Alter Circulating and Intestinal Ceramide and Sphingomyelin Species in Postmenopausal Women
Overview
General Medicine
Authors
Affiliations
BACKGROUNDHigh circulating levels of ceramides (Cer) and sphingomyelins (SM) are associated with cardiometabolic diseases. The consumption of whole fat dairy products, naturally containing such polar lipids (PL), is associated with health benefits, but the impact on sphingolipidome remains unknown.METHODSIn a 4-week randomized controlled trial, 58 postmenopausal women daily consumed milk PL-enriched cream cheese (0, 3, or 5 g of milk PL). Postprandial metabolic explorations were performed before and after supplementation. Analyses included SM and Cer species in serum, chylomicrons, and feces. The ileal contents of 4 ileostomy patients were also explored after acute milk PL intake.RESULTSMilk PL decreased serum atherogenic C24:1 Cer, C16:1 SM, and C18:1 SM species (Pgroup < 0.05). Changes in serum C16+18 SM species were positively correlated with the reduction of cholesterol (r = 0.706), LDL-C (r = 0.666), and ApoB (r = 0.705) (P < 0.001). Milk PL decreased chylomicron content in total SM and C24:1 Cer (Pgroup < 0.001), parallel to a marked increase in total Cer in feces (Pgroup < 0.001). Milk PL modulated some specific SM and Cer species in both ileal efflux and feces, suggesting differential absorption and metabolization processes in the gut.CONCLUSIONMilk PL supplementation decreased atherogenic SM and Cer species associated with the improvement of cardiovascular risk markers. Our findings bring insights on sphingolipid metabolism in the gut, especially Cer, as signaling molecules potentially participating in the beneficial effects of milk PL.TRIAL REGISTRATIONClinicalTrials.gov, NCT02099032, NCT02146339.FUNDINGANR-11-ALID-007-01; PHRCI-2014: VALOBAB, no. 14-007; CNIEL; GLN 2018-11-07; HCL (sponsor).
Role of dietary and nutritional interventions in ceramide-associated diseases.
Wang S, Jin Z, Wu B, Morris A, Deng P J Lipid Res. 2024; 66(1):100726.
PMID: 39667580 PMC: 11754522. DOI: 10.1016/j.jlr.2024.100726.
Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target?.
Foran D, Antoniades C, Akoumianakis I Nutrients. 2024; 16(19).
PMID: 39408263 PMC: 11478599. DOI: 10.3390/nu16193296.
High-fat feeding drives the intestinal production and assembly of C ceramides in chylomicrons.
Mah M, Cao E, Anderson D, Escott A, Tegegne S, Gracia G Sci Adv. 2024; 10(34):eadp2254.
PMID: 39178255 PMC: 11343029. DOI: 10.1126/sciadv.adp2254.
Enzymes of sphingolipid metabolism as transducers of metabolic inputs.
Velazquez F, Luberto C, Canals D, Hannun Y Biochem Soc Trans. 2024; 52(4):1795-1808.
PMID: 39101614 PMC: 11783705. DOI: 10.1042/BST20231442.
Regulation of cellular and systemic sphingolipid homeostasis.
Kuo A, Hla T Nat Rev Mol Cell Biol. 2024; 25(10):802-821.
PMID: 38890457 DOI: 10.1038/s41580-024-00742-y.